ALEC experienced a massive 79% revenue collapse alongside significant balance sheet deterioration, while shifting from "late-stage clinical" to "clinical-stage" company positioning.
The dramatic revenue decline from $100.6M to $21.0M suggests loss of a major partnership or revenue stream, while the company appears to be repositioning itself as earlier-stage despite continuing operations. The combination of falling revenue, widening losses, and substantial equity erosion creates serious concerns about the company's financial trajectory and funding needs.
ALEC's financial profile deteriorated significantly with revenue plummeting 79% to $21.0M while net losses widened 20% to $142.9M despite R&D cost reductions of 34%. The balance sheet shows mixed signals with cash nearly doubling to $65.8M (likely from financing activities) but stockholders' equity collapsing 76% to just $30.6M, indicating substantial dilution or write-downs. Overall, the financial picture suggests a company in distress that recently raised capital but faces fundamental business model challenges given the revenue collapse and widening losses.
Cash position surged 99.3% — strong cash generation or capital raise providing significant financial cushion.
Capex reduced 96.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Revenue declined 79.1% — significant demand weakness or market share loss warrants investigation.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current liabilities reduced — improved short-term financial position and working capital health.
Total assets contracted 37.4% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 37.3% — monitor working capital adequacy and short-term liquidity.
R&D spending cut 33.8% — could signal cost discipline or concerning reduction in innovation investment.
Liabilities reduced 23.1% — deleveraging improves balance sheet strength and financial flexibility.
Net income declined 20.1% — review whether driven by operations, interest costs, or non-recurring items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →